COVID-19 resources & COVID-19 vaccine information

Sword Assay for Human VEGF

Vascular endothelial growth factor (VEGF) was identified as a cell specific mitogen, and a mediator of both angiogenesis and vasculogenesis.1 It contributes to the development of tumors, and elevated levels of VEGF production are able to be detected in tumor cells at the extreme periphery of the tumor.2

In response to tumor-induced hypoxia there have been high levels of VEGF found in various types of tumors, but this is not the case in normal tissue.3 Elevated levels of VEGF result in bronchial asthma, diabetic retinopathy, rheumatoid arthritis, and tumor growth and, the biological properties of VEGF make it an important therapeutic target.

TThis Sword Assay has been optimized for and requires the R&D Systems Human VEGF DuoSet ELISA (Catalog No. DY293B).

Assay Type:

Sandwich ELISA

Product #:


See the Sword Performance Difference


  1. Muller YA, et al.: The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure 1997, 5 (10):1325–1338
  2. Neufeld, G, et al.: Vascular endothelial growth factor and its receptors. The FASEB Journal 1999, 13:9-22.
  3. Soker, S, et al.: Characterization of Novel Vascular Endothelial Growth Factor (VEGF) Receptors on Tumor Cells that Bind VEGF166 via its Exon 7-encoded Domain. The Journal of Biological Chemistry 1996, 271:5761-5767.

Ready to Optimize Your Assay?

Put Sword to the test. Give us 6 days and we’ll show you just how much we can boost your specific assay’s sensitivity, precision, and accuracy. We’ll even assess your first target assay free of charge.

Purchase this Assay

Contact the Sword team today to discuss how best to implement our Human VEGF assay for your needs.


Learn more about Sword’s patented technology and how it can be optimally configured for your specific matrix needs.